X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
RP5063 (brilaroxazine), an atypical antipsychotic new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors, is being developed for the treatment of schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
The net proceeds will fund research and development activities, including the registrational Phase 3 RECOVER-2 trial evaluating RP5063 (brilaroxazine), an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors.
Lead Product(s): Brilaroxazine
Therapeutic Area: Dermatology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 20, 2023
Details:
The net proceeds will fund research and development activities, including the registrational Phase 3 RECOVER-2 trial evaluating RP5063 (brilaroxazine), an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors.
Lead Product(s): Brilaroxazine
Therapeutic Area: Dermatology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 16, 2023
Details:
RP5063 (brilaroxazine), an atypical antipsychotic new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors, is being developed for the treatment of schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
RP5063 (brilaroxazine), an atypical antipsychotic new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors, is being developed for the treatment of schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Dermatology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
RP5063 (brilaroxazine) is selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms. In a multinational, multicenter, double-blind Phase 2 study in 234 patients with acute schizophrenia or schizoaffective disorder.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2023
Details:
RP5063 (brilaroxazine), an atypical antipsychotic new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors, is being developed for the treatment of schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
RP5063 (brilaroxazine, a topical liposomal-gel formulation) is a modulator of D and 5-HT receptors with multifaceted activity that may affect underlying psoriasis pathology.
Lead Product(s): Brilaroxazine
Therapeutic Area: Dermatology Product Name: RP5063
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
Brilaroxazine (RP5063) is a new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
RP5063 (brilaroxazine), a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
Reviva intends to use the net proceeds from the offering to continue the clinical development of brilaroxazine (RP5063) for the treatment of acute and maintenance schizophrenia, and for working capital and other general corporate purposes.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $8.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 06, 2022
Details:
Brilaroxazine (RP5063) is a new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and other psychiatric disorders.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
The Phase 3 RECOVER study with RP5063 (brilaroxazine) demonstrated a safe and well-tolerated profile with no serious treatment-related events to date, in patients with stable schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
Initiation of Phase 3 trial for RP5063 (Brilaroxazine) is expected by end of January 2022 on the basis of results from Phase 2 study met all safety endpoints with no weight gain, no increase in blood sugar and lipids, and no cardiac or endocrine adverse effect.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Details:
Brilaroxazine showed high affinity and selectivity for key serotonin receptors, as it is pharmacologically different from other antipsychotics through its affinity and selectivity for target receptors implicated for schizophrenia and its comorbid symptoms.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2021
Details:
As a result of the completion of the Business Combination, Reviva has become a wholly-owned subsidiary of Reviva Holdings, as the successor to Tenzing. Post merger, the combined company will first look to advance its late-stage lead asset Brilaroxazine (RP5063).
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tenzing Acquisition
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 14, 2020
Details:
The acquisition adds Reviva's lead product candidate, RP5063 (brilaroxazine), for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, to Tenzing's Pipeline.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tenzing
Deal Size: $119.0 million Upfront Cash: Undisclosed
Deal Type: Merger July 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
